stoxline Quote Chart Rank Option Currency Glossary
  
TG Therapeutics, Inc. (TGTX)
15.57  0.13 (0.84%)    03-27 16:00
Open: 15.55
High: 15.615
Volume: 1,402,129
  
Pre. Close: 15.44
Low: 15.055
Market Cap: 2,404(M)
Technical analysis
2024-03-27 4:56:29 PM
Short term     
Mid term     
Targets 6-month :  19.48 1-year :  22.21
Resists First :  16.68 Second :  19.01
Pivot price 15.76
Supports First :  12.89 Second :  10.73
MAs MA(5) :  15.48 MA(20) :  16.29
MA(100) :  15.19 MA(250) :  16.79
MACD MACD :  -0.1 Signal :  0
%K %D K(14,3) :  23.4 D(3) :  22.5
RSI RSI(14): 48.6
52-week High :  35.66 Low :  6.46
Price, MAs and Bollinger Bands

Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.
[ TGTX ] has closed above bottom band by 43.4%. Bollinger Bands are 43.6% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 0 bars. This is a sign that the market may be about to initiate a new trend.

Stock Price Prediction
If tomorrow: Open lower Open higher
High: 15.63 - 15.7 15.7 - 15.77
Low: 14.87 - 14.95 14.95 - 15.03
Close: 15.43 - 15.56 15.56 - 15.69
Company Description

TG Therapeutics, Inc., a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Its therapeutic product candidates include Ublituximab, an investigational glycoengineered monoclonal antibody for the treatment of B-cell non-hodgkin lymphoma, chronic lymphocytic leukemia (CLL), and relapsing forms of multiple sclerosis; and Umbralisib, an oral inhibitor of PI3K-delta and CK1-epsilon for the treatment of CLL, marginal zone lymphoma, and follicular lymphoma. The company also develops Cosibelimab, a human monoclonal antibody of IgG1 subtype that binds to programmed death-ligand 1 (PD-L1) and blocks its interactions with PD-1 and B7.1 receptors; TG-1701 is an orally available and covalently-bound Bruton's tyrosine kinase (BTK) inhibitor that exhibits selectivity to BTK compared to ibrutinib in in vitro kinase screening; and TG-1801, a bispecific CD47 and CD19 antibody. In addition, it has various licensed preclinical programs for BET, interleukin-1 receptor associated kinase-4, and GITR; and collaboration agreements with Checkpoint Therapeutics, Inc., Jiangsu Hengrui Medicine Co., Novimmune SA, Ligand Pharmaceuticals Incorporated, and Jubilant Biosys. The company has strategic alliances with LFB Biotechnologies S.A.S; GTC Biotherapeutics; LFB/GTC LLC; Ildong Pharmaceutical Co. Ltd.; and Rhizen Pharmaceuticals, S A. TG Therapeutics, Inc. was incorporated in 1993 and is headquartered in New York, New York.

Headline News

Wed, 27 Mar 2024
Is the Options Market Predicting a Spike in TG Therapeutics (TGTX) Stock? - Yahoo Movies Canada

Wed, 27 Mar 2024
Brookstone Capital Management Sells 688 Shares of TG Therapeutics, Inc. (NASDAQ:TGTX) - Defense World

Mon, 25 Mar 2024
TG Therapeutics (NASDAQ:TGTX) Has A Somewhat Strained Balance Sheet - Simply Wall St

Tue, 19 Mar 2024
Is TG Therapeutics, Inc.'s (NASDAQ:TGTX) Recent Price Movement Underpinned By Its Weak Fundamentals? - Yahoo Finance

Fri, 08 Mar 2024
TG Therapeutics Announces Schedule of Data Presentations for BRIUMVI® (ublituximab) in Multiple Sclerosis at the ... - Yahoo Finance

Fri, 01 Mar 2024
Results: TG Therapeutics, Inc. Exceeded Expectations And The Consensus Has Updated Its Estimates - Simply Wall St

Financial Analysis
Price to Book Value:
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Outperform
Price to Earnings:
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Underperform
Discounted cash flow:
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Underperform
Return on Assets:
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Neutral
Return on Equity:
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Underperform
Debt to Equity:
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Outperform
Stock Basics & Statistics
Exchange:
NASDAQ
Sector:
Healthcare
Industry:
Biotechnology
Shares Out 0 (M)
Shares Float 154 (M)
Held by Insiders 1.3488e+008 (%)
Held by Institutions 9 (%)
Shares Short 29,120 (K)
Shares Short P.Month 0 (K)
Stock Financials
EPS 2.084e+007
EPS Est Next Qtrly 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) 0
Profit Margin 5.4 %
Operating Margin -28.4 %
Return on Assets (ttm) 4.9 %
Return on Equity (ttm) 11.5 %
Qtrly Rev. Growth 54 %
Gross Profit (p.s.) 370.72
Sales Per Share 1.00283e+008
EBITDA (p.s.) 0
Qtrly Earnings Growth 0 %
Operating Cash Flow 0 (M)
Levered Free Cash Flow -31 (M)
Stock Valuations
PE Ratio 0
PEG Ratio 0
Price to Book value 0
Price to Sales 0
Price to Cash Flow 32.1
Stock Dividends
Dividend 0
Forward Dividend 3.484e+007
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.

StockChart iOS

StoxlineLite iOS

StoxlineLite iOS

OptionCalc iOS

StockChart Android

StoxlineLite Android

StoxlinePro Android

OptionCalc Android